Inhibitors of these checkpoints, such as anti-PD-1 and anti-CTLA-4 antibodies, have been approved to treat ccRCC and other cancers and have shown promise in improving patient outcomes [58]. This evidence concerns the gene CTLA4 and nonpapillary renal cell carcinoma.